Wiesbaden is the second largest city in the Frankfurt Rhine Main region of Germany, with a population of more than 300,000 people. The city is known for its architecture and is one of the oldest spa towns in Europe, with 26 hot springs. It is also home to Velocity’s latest site acquisition.
Velocity acquired InterMed Institut für medizinische Forschung und Arzneimittelsicherheit GmbH (InterMed) at the end of April 2023, making this the company's third site in Germany and fifth in Europe. Velocity began acquiring sites in July last year.
InterMed will become Velocity Wiesbaden, expanding Velocity’s geographical reach and enhancing its patient recruitment capability in Germany — the largest European pharmaceutical market. Velocity plans to acquire and integrate more sites in Germany, enabling closer strategic relationships with Contract Research Organizations (CROs) and drug makers in Europe.
Dominic Clavell, European General Manager, said: “Velocity continues to grow its footprint and patient network in Europe. The InterMed acquisition is one of a number planned in 2023 and supplements the sites we already have in Germany and the UK. The bigger our network is, the more research opportunities we can bring to more people, speeding up drug development and improving lives.
InterMed recruits patients across a broad spectrum of therapeutic areas that are typically treated by family care and general practitioners. The site is currently active in respiratory, dermatology, central nervous system (CNS), vaccine and smoking cessation research, and can conduct studies in all areas of ambulatory medicine.
Marco von Behren, CEO of InterMed and new site director of Velocity Wiesbaden, said: “We have been recruiting patients to clinical trials for over 20 years. Both participants and pharmaceutical companies trust us to conduct clinical research where the highest level of quality and care is instilled into everything we do. We are excited to be integrated into the Velocity network, so we can reach more people and work across more areas of research.”
Velocity will integrate the Wiesbaden site with its technology infrastructure and standard operating procedures (SOP), increasing compliance and enhancing data capture. By implementing Velocity SOPs, we ensure a greater level of standardization and consistency in our approach across our global network of sites, while also allowing for nuance in local regulation.
Together with Velocity’s head of business development in Europe, Évelyne Newton, the site will expand its recruitment capabilities into new disease areas.
